|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(Former name or former address, if changed since last report.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Exhibits.
|
(d) |
Exhibits
|
Exhibit No.
|
Description
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
May 22, 2023
|
ADMA Biologics, Inc.
|
||
By:
|
/s/ Brian Lenz
|
||
Name:
|
Brian Lenz
|
||
Title:
|
Executive Vice President and
|
||
Chief Financial Officer |